APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine for Human Rabies

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Attenuated Vaccine for Human Rabies Market Outlook and Growth Opportunities 2026

30 December 2025194 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine for Human Rabies Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine for Human Rabies Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine for Human Rabies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine for Human Rabies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine for Human Rabies Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine for Human Rabies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attenuated Vaccine for Human Rabies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Attenuated Vaccine for Human Rabies market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Attenuated Vaccine for Human Rabies market include Changchun Zhuoyi Biological Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shandong Yidu Biotechnology Co., Ltd, Ningbo Rongan Biopharmaceutical Co., Ltd, Liaoning Yisheng Biopharmaceutical Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd, Guangzhou Nuocheng Biological Products Co., Ltd, Chengdu Kanghua Biological Products Co., Ltd and AstraZeneca, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Attenuated Vaccine for Human Rabies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Attenuated Vaccine for Human Rabies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Attenuated Vaccine for Human Rabies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Attenuated Vaccine for Human Rabies market size, projected growth trends, production technologies, key applications, and end-use industries.

Attenuated Vaccine for Human Rabies Segment by Company

Changchun Zhuoyi Biological Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Shandong Yidu Biotechnology Co., Ltd

Ningbo Rongan Biopharmaceutical Co., Ltd

Liaoning Yisheng Biopharmaceutical Co., Ltd

Lanzhou Institute of Biological Products Co., Ltd

Guangzhou Nuocheng Biological Products Co., Ltd

Chengdu Kanghua Biological Products Co., Ltd

AstraZeneca

Sanofi Pasteur, Inc

Pfizer Inc

Novartis AG

Merck & Co Inc

GlaxoSmithKline

Cadila Pharmaceuticals Ltd

Attenuated Vaccine for Human Rabies Segment by Type

Vero Cell

Human Diploid Cell

Attenuated Vaccine for Human Rabies Segment by Application

Hospital

Clinic

Attenuated Vaccine for Human Rabies Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Attenuated Vaccine for Human Rabies status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Attenuated Vaccine for Human Rabies market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Attenuated Vaccine for Human Rabies significant trends, drivers, influence factors in global and regions.

6. To analyze Attenuated Vaccine for Human Rabies competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine for Human Rabies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine for Human Rabies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine for Human Rabies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Attenuated Vaccine for Human Rabies market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Attenuated Vaccine for Human Rabies industry.

Chapter 3: Detailed analysis of Attenuated Vaccine for Human Rabies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Attenuated Vaccine for Human Rabies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Attenuated Vaccine for Human Rabies in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Attenuated Vaccine for Human Rabies Industry Trends Table 2. Attenuated Vaccine for Human Rabies Industry Drivers Table 3. Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges Table 4. Attenuated Vaccine for Human Rabies Industry Restraints Table 5. Global Attenuated Vaccine for Human Rabies Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Attenuated Vaccine for Human Rabies Revenue Share by Company (2021-2026) Table 7. Global Attenuated Vaccine for Human Rabies Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Attenuated Vaccine for Human Rabies Sales Volume Share by Company (2021-2026) Table 9. Global Attenuated Vaccine for Human Rabies Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Attenuated Vaccine for Human Rabies Company Ranking, (2024-2026) & (USD Million) Table 11. Global Attenuated Vaccine for Human Rabies Key Company Manufacturing Base & Headquarters Table 12. Global Attenuated Vaccine for Human Rabies Company, Product Type & Application Table 13. Global Attenuated Vaccine for Human Rabies Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Attenuated Vaccine for Human Rabies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vero Cell Table 18. Significant Companies of Human Diploid Cell Table 19. Global Attenuated Vaccine for Human Rabies Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Attenuated Vaccine for Human Rabies Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Attenuated Vaccine for Human Rabies Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Attenuated Vaccine for Human Rabies Sales Volume Share by Type (2021-2026) Table 23. Global Attenuated Vaccine for Human Rabies Sales Volume Share by Type (2027-2032) Table 24. Global Attenuated Vaccine for Human Rabies Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Attenuated Vaccine for Human Rabies Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Attenuated Vaccine for Human Rabies Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Attenuated Vaccine for Human Rabies Sales Value Share by Type (2021-2026) Table 28. Global Attenuated Vaccine for Human Rabies Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Attenuated Vaccine for Human Rabies Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Attenuated Vaccine for Human Rabies Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Attenuated Vaccine for Human Rabies Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Attenuated Vaccine for Human Rabies Sales Volume Share by Application (2021-2026) Table 35. Global Attenuated Vaccine for Human Rabies Sales Volume Share by Application (2027-2032) Table 36. Global Attenuated Vaccine for Human Rabies Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Attenuated Vaccine for Human Rabies Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Attenuated Vaccine for Human Rabies Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Attenuated Vaccine for Human Rabies Sales Value Share by Application (2021-2026) Table 40. Global Attenuated Vaccine for Human Rabies Sales Value Share by Application (2027-2032) Table 41. Global Attenuated Vaccine for Human Rabies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2026) & (K Units) Table 43. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2021-2026) Table 44. Global Attenuated Vaccine for Human Rabies Sales by Region (2027-2032) & (K Units) Table 45. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region (2027-2032) Table 46. Global Attenuated Vaccine for Human Rabies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Attenuated Vaccine for Human Rabies Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Attenuated Vaccine for Human Rabies Sales Value Share by Region (2021-2026) Table 49. Global Attenuated Vaccine for Human Rabies Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Attenuated Vaccine for Human Rabies Sales Value Share by Region (2027-2032) Table 51. Global Attenuated Vaccine for Human Rabies Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Attenuated Vaccine for Human Rabies Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Attenuated Vaccine for Human Rabies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Attenuated Vaccine for Human Rabies Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Attenuated Vaccine for Human Rabies Sales by Country (2021-2026) & (K Units) Table 56. Global Attenuated Vaccine for Human Rabies Sales Market Share by Country (2021-2026) Table 57. Global Attenuated Vaccine for Human Rabies Sales by Country (2027-2032) & (K Units) Table 58. Global Attenuated Vaccine for Human Rabies Sales Market Share by Country (2027-2032) Table 59. Global Attenuated Vaccine for Human Rabies Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Attenuated Vaccine for Human Rabies Sales Value Market Share by Country (2021-2026) Table 61. Global Attenuated Vaccine for Human Rabies Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Attenuated Vaccine for Human Rabies Sales Value Market Share by Country (2027-2032) Table 63. Changchun Zhuoyi Biological Co., Ltd Company Information Table 64. Changchun Zhuoyi Biological Co., Ltd Business Overview Table 65. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 67. Changchun Zhuoyi Biological Co., Ltd Recent Development Table 68. Wuhan Institute of Biological Products Co., Ltd Company Information Table 69. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 70. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 72. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 73. Shandong Yidu Biotechnology Co., Ltd Company Information Table 74. Shandong Yidu Biotechnology Co., Ltd Business Overview Table 75. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 77. Shandong Yidu Biotechnology Co., Ltd Recent Development Table 78. Ningbo Rongan Biopharmaceutical Co., Ltd Company Information Table 79. Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview Table 80. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 82. Ningbo Rongan Biopharmaceutical Co., Ltd Recent Development Table 83. Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information Table 84. Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview Table 85. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 87. Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Development Table 88. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 89. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 90. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 92. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 93. Guangzhou Nuocheng Biological Products Co., Ltd Company Information Table 94. Guangzhou Nuocheng Biological Products Co., Ltd Business Overview Table 95. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 97. Guangzhou Nuocheng Biological Products Co., Ltd Recent Development Table 98. Chengdu Kanghua Biological Products Co., Ltd Company Information Table 99. Chengdu Kanghua Biological Products Co., Ltd Business Overview Table 100. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 102. Chengdu Kanghua Biological Products Co., Ltd Recent Development Table 103. AstraZeneca Company Information Table 104. AstraZeneca Business Overview Table 105. AstraZeneca Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio Table 107. AstraZeneca Recent Development Table 108. Sanofi Pasteur, Inc Company Information Table 109. Sanofi Pasteur, Inc Business Overview Table 110. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 112. Sanofi Pasteur, Inc Recent Development Table 113. Pfizer Inc Company Information Table 114. Pfizer Inc Business Overview Table 115. Pfizer Inc Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 117. Pfizer Inc Recent Development Table 118. Novartis AG Company Information Table 119. Novartis AG Business Overview Table 120. Novartis AG Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio Table 122. Novartis AG Recent Development Table 123. Merck & Co Inc Company Information Table 124. Merck & Co Inc Business Overview Table 125. Merck & Co Inc Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio Table 127. Merck & Co Inc Recent Development Table 128. GlaxoSmithKline Company Information Table 129. GlaxoSmithKline Business Overview Table 130. GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio Table 132. GlaxoSmithKline Recent Development Table 133. Cadila Pharmaceuticals Ltd Company Information Table 134. Cadila Pharmaceuticals Ltd Business Overview Table 135. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio Table 137. Cadila Pharmaceuticals Ltd Recent Development Table 138. Key Raw Materials Table 139. Raw Materials Key Suppliers Table 140. Attenuated Vaccine for Human Rabies Distributors List Table 141. Attenuated Vaccine for Human Rabies Customers List Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Attenuated Vaccine for Human Rabies Product Image Figure 2. Global Attenuated Vaccine for Human Rabies Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine for Human Rabies Sales Value (2021-2032) & (US$ Million) Figure 4. Global Attenuated Vaccine for Human Rabies Sales (2021-2032) & (K Units) Figure 5. Global Attenuated Vaccine for Human Rabies Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Attenuated Vaccine for Human Rabies Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vero Cell Image Figure 10. Human Diploid Cell Image Figure 11. Global Attenuated Vaccine for Human Rabies Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Attenuated Vaccine for Human Rabies Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Attenuated Vaccine for Human Rabies Sales Volume Share by Type (2021-2032) Figure 14. Global Attenuated Vaccine for Human Rabies Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Attenuated Vaccine for Human Rabies Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Attenuated Vaccine for Human Rabies Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Attenuated Vaccine for Human Rabies Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Attenuated Vaccine for Human Rabies Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Attenuated Vaccine for Human Rabies Sales Volume Share by Application (2021-2032) Figure 22. Global Attenuated Vaccine for Human Rabies Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Attenuated Vaccine for Human Rabies Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Attenuated Vaccine for Human Rabies Sales Value Share by Application (2021-2032) Figure 25. Global Attenuated Vaccine for Human Rabies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Attenuated Vaccine for Human Rabies Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Attenuated Vaccine for Human Rabies Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Attenuated Vaccine for Human Rabies Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Attenuated Vaccine for Human Rabies Sales Value (2021-2032) & (US$ Million) Figure 30. North America Attenuated Vaccine for Human Rabies Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Attenuated Vaccine for Human Rabies Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Attenuated Vaccine for Human Rabies Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Attenuated Vaccine for Human Rabies Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Attenuated Vaccine for Human Rabies Sales Value (2021-2032) & (US$ Million) Figure 36. South America Attenuated Vaccine for Human Rabies Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Attenuated Vaccine for Human Rabies Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Attenuated Vaccine for Human Rabies Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Attenuated Vaccine for Human Rabies Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Vero Cell
  • Human Diploid Cell
Applications
  • Hospital
  • Clinic
Companies covered
  • Changchun Zhuoyi Biological Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Shandong Yidu Biotechnology Co., Ltd
  • Ningbo Rongan Biopharmaceutical Co., Ltd
  • Liaoning Yisheng Biopharmaceutical Co., Ltd
  • Lanzhou Institute of Biological Products Co., Ltd
  • Guangzhou Nuocheng Biological Products Co., Ltd
  • Chengdu Kanghua Biological Products Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur, Inc
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • GlaxoSmithKline
  • Cadila Pharmaceuticals Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Attenuated Vaccine for Human Rabies Sales Value (2021-2032)
  4. 1.2.2 Global Attenuated Vaccine for Human Rabies Sales Volume (2021-2032)
  5. 1.2.3 Global Attenuated Vaccine for Human Rabies Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Attenuated Vaccine for Human Rabies Market Dynamics
  1. 2.1 Attenuated Vaccine for Human Rabies Industry Trends
  2. 2.2 Attenuated Vaccine for Human Rabies Industry Drivers
  3. 2.3 Attenuated Vaccine for Human Rabies Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine for Human Rabies Industry Restraints
3 Attenuated Vaccine for Human Rabies Market by Company
  1. 3.1 Global Attenuated Vaccine for Human Rabies Company Revenue Ranking in 2025
  2. 3.2 Global Attenuated Vaccine for Human Rabies Revenue by Company (2021-2026)
  3. 3.3 Global Attenuated Vaccine for Human Rabies Sales Volume by Company (2021-2026)
  4. 3.4 Global Attenuated Vaccine for Human Rabies Average Price by Company (2021-2026)
  5. 3.5 Global Attenuated Vaccine for Human Rabies Company Ranking (2024-2026)
  6. 3.6 Global Attenuated Vaccine for Human Rabies Company Manufacturing Base and Headquarters
  7. 3.7 Global Attenuated Vaccine for Human Rabies Company Product Type and Application
  8. 3.8 Global Attenuated Vaccine for Human Rabies Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Attenuated Vaccine for Human Rabies Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Attenuated Vaccine for Human Rabies Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Attenuated Vaccine for Human Rabies Market by Type
  1. 4.1 Attenuated Vaccine for Human Rabies Type Introduction
  2. 4.1.1 Vero Cell
  3. 4.1.2 Human Diploid Cell
  4. 4.2 Global Attenuated Vaccine for Human Rabies Sales Volume by Type
  5. 4.2.1 Global Attenuated Vaccine for Human Rabies Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Attenuated Vaccine for Human Rabies Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Attenuated Vaccine for Human Rabies Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Attenuated Vaccine for Human Rabies Sales Value by Type
  9. 4.3.1 Global Attenuated Vaccine for Human Rabies Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Attenuated Vaccine for Human Rabies Sales Value by Type (2021-2032)
  11. 4.3.3 Global Attenuated Vaccine for Human Rabies Sales Value Share by Type (2021-2032)
5 Attenuated Vaccine for Human Rabies Market by Application
  1. 5.1 Attenuated Vaccine for Human Rabies Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Attenuated Vaccine for Human Rabies Sales Volume by Application
  5. 5.2.1 Global Attenuated Vaccine for Human Rabies Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Attenuated Vaccine for Human Rabies Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Attenuated Vaccine for Human Rabies Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Attenuated Vaccine for Human Rabies Sales Value by Application
  9. 5.3.1 Global Attenuated Vaccine for Human Rabies Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Attenuated Vaccine for Human Rabies Sales Value by Application (2021-2032)
  11. 5.3.3 Global Attenuated Vaccine for Human Rabies Sales Value Share by Application (2021-2032)
6 Attenuated Vaccine for Human Rabies Regional Sales and Value Analysis
  1. 6.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Attenuated Vaccine for Human Rabies Sales by Region (2021-2032)
  3. 6.2.1 Global Attenuated Vaccine for Human Rabies Sales by Region: 2021-2026
  4. 6.2.2 Global Attenuated Vaccine for Human Rabies Sales by Region (2027-2032)
  5. 6.3 Global Attenuated Vaccine for Human Rabies Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Attenuated Vaccine for Human Rabies Sales Value by Region (2021-2032)
  7. 6.4.1 Global Attenuated Vaccine for Human Rabies Sales Value by Region: 2021-2026
  8. 6.4.2 Global Attenuated Vaccine for Human Rabies Sales Value by Region (2027-2032)
  9. 6.5 Global Attenuated Vaccine for Human Rabies Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Attenuated Vaccine for Human Rabies Sales Value (2021-2032)
  12. 6.6.2 North America Attenuated Vaccine for Human Rabies Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Attenuated Vaccine for Human Rabies Sales Value (2021-2032)
  15. 6.7.2 Europe Attenuated Vaccine for Human Rabies Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Attenuated Vaccine for Human Rabies Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Attenuated Vaccine for Human Rabies Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Attenuated Vaccine for Human Rabies Sales Value (2021-2032)
  21. 6.9.2 South America Attenuated Vaccine for Human Rabies Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Attenuated Vaccine for Human Rabies Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Attenuated Vaccine for Human Rabies Sales Value Share by Country, 2025 VS 2032
7 Attenuated Vaccine for Human Rabies Country-level Sales and Value Analysis
  1. 7.1 Global Attenuated Vaccine for Human Rabies Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Attenuated Vaccine for Human Rabies Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Attenuated Vaccine for Human Rabies Sales by Country (2021-2032)
  4. 7.3.1 Global Attenuated Vaccine for Human Rabies Sales by Country (2021-2026)
  5. 7.3.2 Global Attenuated Vaccine for Human Rabies Sales by Country (2027-2032)
  6. 7.4 Global Attenuated Vaccine for Human Rabies Sales Value by Country (2021-2032)
  7. 7.4.1 Global Attenuated Vaccine for Human Rabies Sales Value by Country (2021-2026)
  8. 7.4.2 Global Attenuated Vaccine for Human Rabies Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Attenuated Vaccine for Human Rabies Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Attenuated Vaccine for Human Rabies Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Attenuated Vaccine for Human Rabies Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun Zhuoyi Biological Co., Ltd
  2. 8.1.1 Changchun Zhuoyi Biological Co., Ltd Company Information
  3. 8.1.2 Changchun Zhuoyi Biological Co., Ltd Business Overview
  4. 8.1.3 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Changchun Zhuoyi Biological Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  6. 8.1.5 Changchun Zhuoyi Biological Co., Ltd Recent Developments
  7. 8.2 Wuhan Institute of Biological Products Co., Ltd
  8. 8.2.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  9. 8.2.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  10. 8.2.3 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Wuhan Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  12. 8.2.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  13. 8.3 Shandong Yidu Biotechnology Co., Ltd
  14. 8.3.1 Shandong Yidu Biotechnology Co., Ltd Company Information
  15. 8.3.2 Shandong Yidu Biotechnology Co., Ltd Business Overview
  16. 8.3.3 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Shandong Yidu Biotechnology Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  18. 8.3.5 Shandong Yidu Biotechnology Co., Ltd Recent Developments
  19. 8.4 Ningbo Rongan Biopharmaceutical Co., Ltd
  20. 8.4.1 Ningbo Rongan Biopharmaceutical Co., Ltd Company Information
  21. 8.4.2 Ningbo Rongan Biopharmaceutical Co., Ltd Business Overview
  22. 8.4.3 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Ningbo Rongan Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  24. 8.4.5 Ningbo Rongan Biopharmaceutical Co., Ltd Recent Developments
  25. 8.5 Liaoning Yisheng Biopharmaceutical Co., Ltd
  26. 8.5.1 Liaoning Yisheng Biopharmaceutical Co., Ltd Company Information
  27. 8.5.2 Liaoning Yisheng Biopharmaceutical Co., Ltd Business Overview
  28. 8.5.3 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Liaoning Yisheng Biopharmaceutical Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  30. 8.5.5 Liaoning Yisheng Biopharmaceutical Co., Ltd Recent Developments
  31. 8.6 Lanzhou Institute of Biological Products Co., Ltd
  32. 8.6.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  33. 8.6.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  34. 8.6.3 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lanzhou Institute of Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  36. 8.6.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  37. 8.7 Guangzhou Nuocheng Biological Products Co., Ltd
  38. 8.7.1 Guangzhou Nuocheng Biological Products Co., Ltd Company Information
  39. 8.7.2 Guangzhou Nuocheng Biological Products Co., Ltd Business Overview
  40. 8.7.3 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Guangzhou Nuocheng Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  42. 8.7.5 Guangzhou Nuocheng Biological Products Co., Ltd Recent Developments
  43. 8.8 Chengdu Kanghua Biological Products Co., Ltd
  44. 8.8.1 Chengdu Kanghua Biological Products Co., Ltd Company Information
  45. 8.8.2 Chengdu Kanghua Biological Products Co., Ltd Business Overview
  46. 8.8.3 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Chengdu Kanghua Biological Products Co., Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  48. 8.8.5 Chengdu Kanghua Biological Products Co., Ltd Recent Developments
  49. 8.9 AstraZeneca
  50. 8.9.1 AstraZeneca Company Information
  51. 8.9.2 AstraZeneca Business Overview
  52. 8.9.3 AstraZeneca Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AstraZeneca Attenuated Vaccine for Human Rabies Product Portfolio
  54. 8.9.5 AstraZeneca Recent Developments
  55. 8.10 Sanofi Pasteur, Inc
  56. 8.10.1 Sanofi Pasteur, Inc Company Information
  57. 8.10.2 Sanofi Pasteur, Inc Business Overview
  58. 8.10.3 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sanofi Pasteur, Inc Attenuated Vaccine for Human Rabies Product Portfolio
  60. 8.10.5 Sanofi Pasteur, Inc Recent Developments
  61. 8.11 Pfizer Inc
  62. 8.11.1 Pfizer Inc Company Information
  63. 8.11.2 Pfizer Inc Business Overview
  64. 8.11.3 Pfizer Inc Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Inc Attenuated Vaccine for Human Rabies Product Portfolio
  66. 8.11.5 Pfizer Inc Recent Developments
  67. 8.12 Novartis AG
  68. 8.12.1 Novartis AG Company Information
  69. 8.12.2 Novartis AG Business Overview
  70. 8.12.3 Novartis AG Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Novartis AG Attenuated Vaccine for Human Rabies Product Portfolio
  72. 8.12.5 Novartis AG Recent Developments
  73. 8.13 Merck & Co Inc
  74. 8.13.1 Merck & Co Inc Company Information
  75. 8.13.2 Merck & Co Inc Business Overview
  76. 8.13.3 Merck & Co Inc Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Merck & Co Inc Attenuated Vaccine for Human Rabies Product Portfolio
  78. 8.13.5 Merck & Co Inc Recent Developments
  79. 8.14 GlaxoSmithKline
  80. 8.14.1 GlaxoSmithKline Company Information
  81. 8.14.2 GlaxoSmithKline Business Overview
  82. 8.14.3 GlaxoSmithKline Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 GlaxoSmithKline Attenuated Vaccine for Human Rabies Product Portfolio
  84. 8.14.5 GlaxoSmithKline Recent Developments
  85. 8.15 Cadila Pharmaceuticals Ltd
  86. 8.15.1 Cadila Pharmaceuticals Ltd Company Information
  87. 8.15.2 Cadila Pharmaceuticals Ltd Business Overview
  88. 8.15.3 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Cadila Pharmaceuticals Ltd Attenuated Vaccine for Human Rabies Product Portfolio
  90. 8.15.5 Cadila Pharmaceuticals Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Attenuated Vaccine for Human Rabies Value Chain Analysis
  2. 9.1.1 Attenuated Vaccine for Human Rabies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Attenuated Vaccine for Human Rabies Sales Mode & Process
  6. 9.2 Attenuated Vaccine for Human Rabies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Attenuated Vaccine for Human Rabies Distributors
  9. 9.2.3 Attenuated Vaccine for Human Rabies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst